FDA Approves Abilify Maintena for Schizophrenia
The US Food and Drug Administration (FDA) has approved ABILIFY MAINTENA™ (aripiprazole) for extended release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.
